The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

BACKGROUND: Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respiratory symptoms, assessed using the Evaluating Respiratory Symptoms in COPD (E-RS(™...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Respir Res
Autores principales: Jones, Paul W., Leidy, Nancy K., Hareendran, Asha, Lamarca, Rosa, Chuecos, Ferran, Garcia Gil, Esther
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877996/
https://ncbi.nlm.nih.gov/pubmed/27215749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0372-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares